Academic Vascular Surgical Unit, Hull York Medical School & University of Hull, Hull Royal Infirmary, Anlaby Road, Hull HU3 2JZ, UK.
Atherosclerosis. 2012 Mar;221(1):18-33. doi: 10.1016/j.atherosclerosis.2011.12.005. Epub 2011 Dec 9.
Several studies have assessed the effect of angiotensin converting enzyme inhibitors (ACEIs) on arterial stiffness and wave reflections as measured by pulse wave velocity (PWV) and augmentation index (AIx), respectively. We conducted a meta-analysis to investigate this effect in comparison to placebo and to other antihypertensive agents. Additionally, we investigated this effect when ACEIs are combined with other antihypertensive agents and in comparison to a combination of antihypertensive agents.
MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to May 2011 on randomised controlled trials (RCTs) which assessed the effect of ACEIs on arterial stiffness vs. placebo or no treatment and ACEIs vs. angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), β-blockers and diuretics. RCTs which assessed the effect of ACEIs combined with other antihypertensives or compared ACEIs with a combination of antihypertensives were also sought. Data from included RCTs were pooled with use of fixed and random effects meta-analysis of the weighted mean change differences between the comparator groups. Heterogeneity across studies was assessed with the I(2) statistic.
In 5 trials including 469 patients, treatment with ACEIs (n=227) vs. placebo (n=216) significantly reduced PWV (pooled mean change difference -1.69, 95% C.I. -2.05, -1.33, p<0.00001 with insignificant heterogeneity). In 9 trials which included 378 patients, treatment with ACEIs (n=178) insignificantly reduced PWV when compared with other antihypertensives (ARBs, CCBs, β-blockers, diuretics and a combination of ACEI and ARB) (n=220) (pooled mean change difference -0.19, 95% C.I. -0.59, 0.21, p=0.36, I(2)=0%). ACEI effect on AIx in comparison to placebo was assessed in 7 trials. Treatment with ACEIs significantly reduced AIx (pooled mean change difference -3.79, 95% C.I. -5.96, -1.63, p=0.0006) with significant heterogeneity. In 7 trials, treatment with ACEIs significantly reduced AIx when compared with other antihypertensives (pooled mean change difference -1.84, 95% C.I. -3, -0.68, p=0.002, I(2)=32%, p for heterogeneity=0.11). However, this effect was only significant when compared with β-blockers (pooled mean change difference -1.6, 95% C.I. -2.84, -0.36, p=0.01). Mean BP differences between baseline and end of treatment did not predict the treatment (ACEI) induced changes in PWV.
ACEIs reduce PWV and AIx which are markers of arterial stiffness and wave reflections in patients with different pathological conditions. However, due to the lack of high quality and properly powered RCTs, it is not clear whether ACEIs are superior to other antihypertensive agents in their effect on arterial stiffness. The ability of ACEIs to reduce arterial stiffness (PWV) seems to be independent of its ability to reduce BP.
几项研究评估了血管紧张素转换酶抑制剂(ACEI)对脉搏波速度(PWV)和增强指数(AIx)分别测量的动脉僵硬和波反射的影响。我们进行了一项荟萃分析,以研究与安慰剂和其他抗高血压药物相比的这种作用。此外,我们还研究了 ACEI 与其他抗高血压药物联合使用时以及与抗高血压药物联合使用时的这种作用。
从创建到 2011 年 5 月,我们在 MEDLINE、EMBASE 和 Cochrane 对照试验中心注册库(CENTRAL)中搜索了评估 ACEI 对动脉僵硬的影响与安慰剂或不治疗以及 ACEI 与血管紧张素受体阻滞剂(ARB)、钙通道阻滞剂(CCB)、β-受体阻滞剂和利尿剂相比的随机对照试验(RCT)。还寻找了评估 ACEI 与其他降压药联合使用的效果或比较 ACEI 与降压药联合使用的 RCT。纳入 RCT 的数据使用固定和随机效应荟萃分析来比较比较组之间的加权平均变化差异进行汇总。使用 I(2)统计量评估研究之间的异质性。
在包括 469 名患者的 5 项试验中,ACEI 治疗(n=227)与安慰剂(n=216)相比,PWV 显著降低(汇总平均变化差异-1.69,95%CI-2.05,-1.33,p<0.00001,异质性不显著)。在包括 378 名患者的 9 项试验中,ACEI 治疗(n=178)与其他抗高血压药物(ARB、CCB、β-受体阻滞剂、利尿剂和 ACEI 和 ARB 的联合治疗)(n=220)相比,PWV 降低不显著(汇总平均变化差异-0.19,95%CI-0.59,0.21,p=0.36,I(2)=0%)。在 7 项试验中评估了 ACEI 与安慰剂相比对 AIx 的影响。ACEI 治疗显著降低 AIx(汇总平均变化差异-3.79,95%CI-5.96,-1.63,p=0.0006),异质性显著。在 7 项试验中,ACEI 治疗与其他抗高血压药物相比,AIx 显著降低(汇总平均变化差异-1.84,95%CI-3,-0.68,p=0.002,I(2)=32%,p 异质性=0.11)。然而,与β-受体阻滞剂相比,这种效果仅具有统计学意义(汇总平均变化差异-1.6,95%CI-2.84,-0.36,p=0.01)。治疗前后平均血压差异不能预测 PWV 治疗(ACEI)引起的变化。
ACEI 降低了不同病理条件下患者的 PWV 和 AIx,这些都是动脉僵硬和波反射的标志物。然而,由于缺乏高质量和适当功率的 RCT,尚不清楚 ACEI 在其对动脉僵硬的作用方面是否优于其他抗高血压药物。ACEI 降低动脉僵硬(PWV)的能力似乎与其降低血压的能力无关。